Genomic, immunological, and clinical analysis of COVID‐19 vaccine breakthrough infections in Beijing, China

Di Tian(Capital Medical University), Wenbo Xu(Shenyang Institute of Automation), Jing Wen(East China Normal University), Zhihai Chen(Capital Medical University), Ziruo Ge(Capital Medical University), Yao Zhang(Fudan University), Yang Song(National Institute for Viral Disease Control and Prevention), Peng Yang(Rutgers, The State University of New Jersey), Hongxia Guo(National Institute for Viral Disease Control and Prevention), Yanli Xu(Capital Medical University), Xingxiang Ren(Capital Medical University), Man Zhang(Ecosystem Sciences), Yang Pan(Beijing Center for Disease Prevention and Control)
Journal of Medical Virology
February 3, 2022
10.1002/jmv.27636
Cited by 20

Related Papers

A Novel Coronavirus from Patients with Pneumonia in China, 2019
|New England Journal of Medicine|2020|30.5k
Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding
|The Lancet|2020|12.6k
The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice
|Nature|2020|1.2k
Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2
|Cell|2020|802
Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial
|The Lancet|2016|202